JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...
Patient records showed Jada was able to control abnormal bleeding within five minutes in 73.8% of vaginal births and 62.2% of cesarean births. (Getty Images) The women’s health company Organon has put ...
The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...
Please provide your email address to receive an email when new articles are posted on . Treatment success for the JADA system was high for both vaginal and cesarean births. Overall, 2.8% of women in ...
Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...
A new device provides rapid hemorrhage management, has minimal inflammatory effects, and provides infection control. Most notably, it has tunable rates of biodegradation, making it usable for both ...
It’s Black Maternal Health Week. Here’s everything you should know to protect yourself and those you love. As a board-certified obstetrician and gynecologist, Kameelah Phillips, MD, knows what it ...
The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results